Orthocell to Outline March-Quarter Results and Remplir Rollout in Investor Webinar

An announcement from Orthocell Ltd ( (AU:OCC) ) is now available.

Orthocell Ltd will release its quarterly results for the period ended 31 March 2026 on 20 April and host an investor webinar the same day, led by its chair, chief executive and chief financial officer. The briefing will cover financial performance and provide an operational update, with particular focus on the U.S. rollout of its Remplir nerve repair product and its use in prostate cancer surgeries in Australia, signalling continued commercial progress for its regenerative portfolio.

The update is expected to give investors greater visibility into early sales traction from Remplir, which recently gained U.S. clearance, and into broader adoption trends across key markets. By highlighting its distribution network expansion and clinical applications in nerve reconstruction, Orthocell is positioning itself as a growing player in regenerative medicine, with the webinar serving as a platform to reinforce its strategy and engage shareholders on near-term operational milestones.

The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

More about Orthocell Ltd

Orthocell Ltd is a regenerative medicine company focused on restoring mobility through products that repair bone and soft tissue injuries. Its portfolio includes collagen-based medical devices for dental and orthopaedic reconstruction, such as Striate+ for dental guided bone regeneration, and Remplir for peripheral nerve repair, alongside autologous cell therapies targeting damaged tendon and cartilage tissue across key global markets.

Average Trading Volume: 423,293

Technical Sentiment Signal: Hold

Current Market Cap: A$222.5M

See more insights into OCC stock on TipRanks’ Stock Analysis page.